Our story ​

In Correggio, Italy, early 1920, we find Giovanni Recordati working in a tiny laboratory installed in the back of his family’s pharmacy. With a passion to help people, he’s trying to find better combinations of existing treatments, as he believes more can be done to help those living with conditions that significantly impact their ability to live a full life. 

In 1926, and at only 28 years old, Giovanni leaves the pharmacy to create “Laboratorio Farmacologico Reggiano”. Here, he pioneers the production of medicines focused on chronic conditions – and within just two decades his small team grows to over 300 people. He sadly passes in 1952, before he could see his ambitious plans for expansion come to life, but his eldest son Arrigo and the generations thereafter, protected his legacy – and his dream lived on in the heart of his family, and the growing family in the Recordati company.
Learn More

Recordati started by focussing on where help was needed most – common illnesses that affect large populations day-to-day. The illnesses right in front of us, where we knew more could be done to help – from heart conditions, mental illness to prostate cancer. But as the world has grown around us, so has the need. 

Discover Our Operations

With the huge benefits of medical innovation, come discoveries of rare, devastating conditions, where for some, no treatment exists at all – with 7,000 known rare diseases, less than 10% have an available treatment option. So, since 2007, Recordati has also focused on helping the few who suffer from little known conditions such as Cushing’s disease, acromegaly, porphyria to rare cancers like high-risk neuroblastoma.

Today, almost 100 years and three generations later, Giovanni’s focus and determination lives on. His company, Recordati, is now a global pharmaceutical group, listed on the Italian stock exchange, with over 4,450 employees.

Developing and making medicines are still at our core, with two chemical plants and seven manufacturing sites worldwide, and a focus to continuously develop new specialties, new treatments, and invest in medical innovations that bring a brighter future.

Every day, in every way, we do everything possible so that people can live full lives – we do this together, working closely with suppliers, partners and doctors from Brazil to the Far East, in around 150 countries. We will always continue to build with our people, planet, community, and our own roots, at our heart. 

Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through partnerships & acquisitions across all our businesses.

MILESTONES

1926

Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)

1953

Transfer of headquarters to Milan

1961

Recordati – Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones

1963

Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia

1984

Listing on the Italian Stock Exchange

1995

Beginning the process of internationalisation – Establishment of a subsidiary in Spain, now called Casen Recordati

1999

Acquisition of Doms Adrian (France)

2000

Acquisition of Bouchara (France)

2001

Establishment of Bouchara Recordati in France

2005
  • Acquisition of Merckle Recordati in Germany, now Recordati Pharma
  • Establishment of Recordati Pharmaceuticals in the United Kingdom
  • Establishment of Recordati Hellas in Greece
  • Establishment of the new pharmaceutical chemical plant in Cork, Ireland
2006

Acquisition of the Grupo Jaba companies in Portugal, today Jaba Recordati

2007

Entry to the rare diseases sector with the acquisition of Orphan Europe, now Recordati Rare Diseases

2008
  • Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
  • Acquisition of Yeni Ilaç in Turkey, today Recordati Ilaç
2009

Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia, today Herbacos Recordati

2010

Acquisition of ArtMed International in Romania, now Recordati Romania

2011

Acquisition of Dr. F. Frik Ilaç in Turkey, now Recordati Ilaç

2012
  • Entry into the US market rare diseases sector
  • Acquisition of product portfolio for the treatment of a number of rare diseases in the US
  • Acquisition of Farma-Projekt in Poland, now Recordati Polska
2013
  • Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia, now Opalia Recordati
  • Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain, now Casen Recordati
2015

Establishment of new subsidiaries in Brazil, Mexico and Colombia 

2016
  • SPC and OTC portfolio strengthened
  • Acquisition of Italchimici in Italy
  • Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
2017
  • Acquisition of Natural Point in Italy
  • Acquisition of Tonipharm in France 
  • Establishment of new subsidiaries in Japan and Australia
2019
  • Expansion of the rare diseases product portfolio: entry into the endocrinology sector
  • Establishment of Recordati Bulgaria
2022
  • Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on rare diseases and niche oncology
2023

  • Recordati announces an agreement with GSK to commercialize Avodart® (dutasteride) and Combodart®/Duodart®

In Partenza Recordati.com

Stai per lasciare recordati.com per accedere al sito dedicato alle carriere di Recordati

ACCETTARE
TORNA INDIETRO

Leaving Recordati.com

You are now leaving recordati.com to enter Recordati’s dedicated career site

ACCEPT
GO BACK

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.